Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728718 | 0.86 | KLK7 (0.38) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL17728719 | 0.86 | KLK7 (0.38) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL597446 | 0.85 | FASN (0.36) | — | |
| SCHEMBL597445 | 0.85 | FASN (0.36) | — | |
| SCHEMBL1908588 | 0.85 | KLK7 (0.41) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598151 | 0.85 | KLK7 (0.41) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL599647 | 0.85 | KLK7 (0.41) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL18922324 | 0.84 | KLK7 (0.39) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL17728760 | 0.83 | ALDH1A1 (0.48) | KLK7KLK5 | |
| SCHEMBL17728758 | 0.83 | ALDH1A1 (0.48) | KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-8846913-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846913-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | KLK7 232/4885KLK5 113/4885PRSS1 52/4885 |
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KLK7 241/4885KLK5 112/4885PRSS1 63/4885 |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | KLK7 232/4885KLK5 113/4885PRSS1 52/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | KLK7 232/4885KLK5 113/4885PRSS1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.